MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Progressive myoclonus ataxia and resting tremor in hypoceruloplasminemia

    L. Pollini, M. Novelli, F. Nardecchia, K. Bernardi, E. Colacino, F. Pisani, V. Leuzzi, S. Galosi (Rome, Italy)

    Objective: To describe two familiar cases of hypoceruloplasminemia presenting with movement disorders Background: Aceruloplasminemia is a metabolic disorder caused by mutations in the ceruloplasmin (CP)…
  • 2023 International Congress

    Subjective cognitive complaints in participants of the Healthy Brain Ageing (HeBA) study

    S. Jónsdóttir, C. Pauly, O. Tsurkalenko, E. Thiry, AM. Hanff, T. Marques, C. Horlings, A. Garrido, C. Vega, S. Schade, P. Mahlknecht, C. Gomes, S. Ghosh, K. Rege, R. Rawal, D. Mcintyre, K. Seppi, M. Martí, C. Trenkwalder, E. Tolosa, W. Poewe, V. Satagopam, R. Krüger, B. Mollenhauer (Heisdorf, Luxembourg)

    Objective: To investigate the prevalence of subjective cognitive complaints (SCC) from Healthy Brain Ageing Study (HeBA) participants in Luxembourg, and explore risk factors prevalence which…
  • 2023 International Congress

    Paraneoplastic cerebellar degeneration due to an anti-SOX 1 antibody manifesting as head tremors, without evidence of underlying malignancy

    K. Sai Krishna, F. Mustafa, R K. Singh, A. Das, B. Mishra, A. Elavarsi, D. Vibha, M. Tripathy, S. Gaikwad (NEW DELHI, India)

    Objective: To describe a case of Paraneoplastic Cerebellar degeneration (PCD) linked to anti-SOX 1 antibody with no discernible malignancy. Background: PCD is a rare neurological…
  • 2023 International Congress

    An Algorithmic Approach to Assessing Cognitive Functioning in Individuals with REM Sleep Behavior Disorder

    G. Schneider, A. Avidan, D. Bliwise, S. Criswell, E. During, J. Elliott, L. Forsberg, J-F. Gagnon, M. Howell, D. Huddleston, A. Keil, J. Lee-Iannotti, M. Lim, J. Mcleland, M. Miglis, E. Mignot, R. Postuma, C. Schenck, D. Shprecher, E. ST. Louis, A. Videnovic, B. Boeve, Y-E. Ju, J. Fields (Rochester, USA)

    Objective: To apply an algorithmic approach to interpretation of cognitive data to assess cognitive impairment in RBD participants. Background: Cognitive changes in emerging neurodegenerative disease…
  • 2023 International Congress

    Parkinson’s disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.

    H. Dourado, C. Lobo, G. Procópio, AE. Lima, MA. Silveira, L. de Almeida, IJ. Oliveira, G. Valença (Salvador, Brazil)

    Objective: To describe the prevalence of Parkinson's Disease (PD) associated psychosis (PDAP) at a Brazilian movement disorders outpatient and to evaluate its associated factors. Background:…
  • 2023 International Congress

    Transcranical Pulse Stimulation in Parkinson’s rest tremor: a pilot study.

    P. Manganotti, M. Liccari, TMI. Lombardo, M. Michelutti, M. Catalan (Trieste, Italy)

    Objective: The goal of this paper is to explore a possible effect of TPS on the PD rest tremor circuit, stimulating the motor cortex (M1)…
  • 2023 International Congress

    Utility of neurophysiological markers in clinical management of subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson’s disease (PD)-a case report.

    K. Markopoulou, P. Warnke (Evanston, USA)

    Objective: Use local field potentials (LFP) to inform longitudinal clinical decision making. Background: Genetic status, clinical and stimulation parameters affect outcomes in PD STN DBS.…
  • 2023 International Congress

    Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease and motor fluctuations: Results from the Phase 3 randomized, active-controlled BouNDless study

    O. Rascol, A. Albanese, A. Ellenbogen, J. Ferreira, N. Giladi, T. Gurevich, S. Hassin-Baer, J. Hernandez-Vara, S. Isaacson, K. Kieburtz, P. Lewitt, L. Lopez-Manzanares, CW. Olanow, R. Pahwa, W. Poewe, H. Sarva, F. Stocchi, T. Yardeni, L. Adar, L. Salin, N. Lopes, N. Sasson, R. Case, A. Espay (Toulouse, France)

    Objective: Determine the efficacy, safety, and tolerability of ND0612 versus oral immediate-release levodopa/carbidopa (IR-LD/CD) in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background: ND0612…
  • 2023 International Congress

    Eye tracking paradigm to identify disease-specific behavioral biomarkers in neurodegeneration

    M. Habibi, B. Coe, D. Brien, H. Riek, A. Janzen, W. Oertel, D. Munoz (Marburg, Germany)

    Objective: Rapid-eye movement (REM) sleep behavior disorder (RBD) has been identified as the most specific and common prodromal stages of α-synucleinopathies (αSYN) such as Parkinson's…
  • 2023 International Congress

    Pathological neuronal Oscillations in an animal model of Rapid-Onset Dystonia-Parkinsonism

    M. Möller, J. Nieweler, M. Bähr, C. Van-Riesen (Göttingen, Germany)

    Objective: The aim of our study was to investigate neuronal network activity in the basal ganglia (BG) and cerebellum (CB) in Rapid-Onset Dystonia-Parkinsonism (RDP). Background:…
  • « Previous Page
  • 1
  • …
  • 304
  • 305
  • 306
  • 307
  • 308
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley